The Regulatory Gamble: How Delayed FDA Postmarket Studies Leave Patients and the Healthcare System Exposed

The system of drug and medical device regulation in the United States relies heavily on a delicate compromise: allowing life-saving therapies to reach the market quickly based on limited early data, with the understanding that manufacturers will complete rigorous, long-term safety and efficacy studies afterward. However, an analysis of federal regulatory data reveals that this postmarket oversight framework frequently breaks down. Hundreds of mandated postmarket studies are chronically delayed, leaving patients, physicians, and public payers in the dark about the true long-term risks and benefits of widely used medical products.

This systemic vulnerability is exemplified by the regulatory battles surrounding high-profile pharmaceuticals and medical devices, where postmarket delays have spanned years or even decades. As policy shifts at the federal level aim to accelerate product approvals further—such as reducing the default clinical trial requirement from two trials to one—public health experts warn that the pressure on the post-approval oversight system will only intensify.

The Scope and Mechanics of Postmarket Delays

Postmarket requirements and commitments are studies or clinical trials that companies agree to conduct after receiving regulatory clearance. These studies are designed to answer critical questions that could not be resolved during the initial review phase, such as evaluating rare side effects, determining safety in specific vulnerable populations like pregnant women, or verifying clinical benefits for products granted accelerated approval.

Yet, a review of federal databases highlights a pervasive pattern of missed deadlines and stalled research. Nearly 600 postmarket studies involving hundreds of biological products and drugs are running behind schedule. In many cases, final reports that were originally due years ago remain unwritten, while enrollment targets for ongoing clinical trials lag severely behind projections. Medical device pathways show a similar trend, with numerous post-approval evaluations stalling due to recruitment challenges, logistical hurdles, or shifting corporate priorities.

For instance, the CustomFlex Artificial Iris—a prosthetic intended to replace damaged or missing irises—faced significant delays after its 2018 approval, with a mandatory pediatric study reporting zero patient enrollment years into the mandate due to the extreme rarity of the underlying condition. Similarly, post-approval safety evaluations for therapeutics like Pfizer’s Paxlovid in pregnant populations have missed initial completion milestones. The Scandinavian Total Ankle Replacement system similarly lagged in fulfilling comprehensive long-term patient follow-up goals, even as hundreds of subjects experienced subsequent surgical revisions or adverse events.

Financial and Operational Incentives for Delay

From an economic perspective, the current regulatory structure creates few disincentives for companies to drag their feet on postmarket research. While studies remain incomplete or delayed, manufacturers can continue to market, distribute, and profit from their products.

Government health programs bear a substantial financial burden under this dynamic. A landmark analysis by the Department of Health and Human Services (HHS) Office of Inspector General estimated that Medicare and Medicaid spent more than $18 billion over a brief four-year window on drugs with accelerated approvals whose confirmatory trials were incomplete past their original deadlines. When products ultimately remain on the market for years without definitive proof of long-term efficacy or safety, public and private insurance programs risk funding therapies that may deliver marginal or nonexistent benefits while exposing patients to unforeseen toxicities.

The Case of Tavneos and Accelerated Scrutiny

The risks associated with delayed postmarket verification and rapid approvals are sharply underscored by the trajectory of Tavneos (avacopan), an autoimmune drug originally developed by ChemoCentryx and later acquired by pharmaceutical giant Amgen. When the FDA weighed the approval of Tavneos to treat severe ANCA-associated vasculitis—a group of rare, life-threatening autoimmune diseases that attack blood vessels—agency experts strongly advised against authorization, pointing to severely limited safety data.

Despite these warnings, the FDA approved the medication in 2021 with a mandate for a multi-year postmarket study involving 300 patients to assess long-term safety, including potential risks of drug-induced liver injury. Years into the mandate, the study remains severely delayed, having enrolled only a small fraction of the required patient cohort. Amgen attributed the recruitment lag to the difficulties of finding patients willing to risk receiving a placebo when alternative therapies are available.

Concurrently, the regulatory landscape for Tavneos shifted dramatically. The FDA identified dozens of cases of serious liver injury potentially linked to the medication and initiated proceedings to withdraw approval entirely, alleging that initial clinical trial results had been manipulated to overstate effectiveness. While Amgen has vigorously defended the integrity of the data and contested the withdrawal effort, international regulators have taken decisive action; the European Union officially revoked its marketing authorization for the drug. Generating hundreds of millions of dollars in annual global sales, Tavneos illustrates the commercial stakes involved when post-approval safety signals clash with corporate financial interests.

Accelerated Approvals and the Burden of False Hope

The challenges facing postmarket oversight are not limited to traditional drug approvals; they are equally pronounced in the pathway of accelerated approvals designed for serious or life-threatening conditions with unmet medical needs.

In 2016, the FDA granted accelerated approval to Exondys 51 (eteplirsen), a treatment for Duchenne muscular dystrophy manufactured by Sarepta Therapeutics. Agency scientists opposed the greenlight, arguing that the drug’s clinical benefit was unproven and that approval would offer false hope to patients and families facing a devastating degenerative condition. The FDA conditioned its approval on Sarepta conducting confirmatory trials to verify clinical utility, warning that failure to act with due diligence could result in the revocation of marketing rights.

Nearly a decade after its initial approval, the required confirmatory study missed its final report milestones, and the trial was formally classified as delayed due to recruitment difficulties in a small patient population. Meanwhile, Exondys 51 became one of the most expensive medications in the United States, commanding annual price tags ranging from $750,000 to $1.5 million and generating hundreds of millions of dollars in annual revenue for its manufacturer. Historical precedent suggests that once a drug secures accelerated approval and penetrates the commercial market, removing it—even in the absence of verified clinical benefit—remains an immense regulatory hurdle.

Policy Shifts and Future Implications

The debate over postmarket accountability arrives at a critical juncture for federal health policy. Recent administrative and legislative pushes to expedite drug reviews—such as the FDA’s National Priority Voucher program and policies reducing the default requirement for pre-approval clinical trials from two studies down to one—are designed to lower development costs and bring innovative therapies to patients faster.

However, medical researchers and independent analysts caution that shrinking pre-approval evidentiary requirements inevitably transfers an unsustainable burden onto the post-approval framework. If drugs enter the market with fewer baseline clinical trials, the societal reliance on timely, rigorous postmarket studies to catch safety signals and confirm efficacy becomes absolute.

Federal defenders of the regulatory process maintain that delays in postmarket research can occasionally stem from legitimate logistical hurdles, such as rare disease patient recruitment, and that a delay should not automatically be interpreted as evidence of an unresolved safety defect. The HHS and pharmaceutical manufacturers emphasize their ongoing commitments to fulfilling post-approval obligations and monitoring real-world safety data.

Nevertheless, public health advocates argue that without stricter enforcement mechanisms—such as automatic financial penalties, expedited market withdrawal procedures for overdue studies, or more transparent public accountability metrics—the postmarket study system will remain functionally toothless. Until structural reforms bridge the gap between regulatory mandates and actual corporate execution, patients, physicians, and healthcare payers will continue to navigate a landscape defined by clinical uncertainty.